UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30

Universe Pharmaceuticals INC

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026

$3.76−0.17 (-4.33%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Universe Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Universe Pharmaceuticals filed with the SEC

Sep 1, 2026, 5:25 PM ET
NOTICE AND PROXY STATEMENT OF 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED SEPTEMBER 1, 2026, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
Sep 1, 2026, 5:25 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Jul 29, 2026, 4:05 PM ET
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
EX-99.1 to Form 6-K
Jul 29, 2026, 4:05 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Jun 26, 2026, 4:06 PM ET
PRESS RELEASE -- UNIVERSE PHARMACEUTICALS INC ANNOUNCES STRATEGIC ACQUISITION TO EXPAND PHARMACEUTICAL PATENT PORTFOLIO
EX-99.1 to Form 6-K
Feb 11, 2026, 4:06 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC ANNOUNCES EFFECTIVE DATE OF DUAL-CLASS SHARE STRUCTURE
EX-99.1 to Form 6-K
Jul 29, 2025, 4:05 PM ET
NOTICE AND PROXY STATEMENT OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED JULY 29, 2025, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
Jul 29, 2025, 4:05 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Mar 20, 2025, 8:33 AM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC ANNOUNCES SHARE CONSOLIDATION
EX-99.1 to Form 6-K
Feb 25, 2025, 4:11 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC RECEIVES STAFF DETERMINATION NOTICE FROM NASDAQ RELATED TO DELAYED ANNUAL REPORT
EX-99.1 to Form 6-K
Feb 11, 2025, 4:10 PM ET
NOTICE AND PROXY STATEMENT OF MARCH 2025 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS, DATED FEBRUARY 11, 2025, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
Feb 11, 2025, 4:10 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE MARCH 2025 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Feb 3, 2025, 4:10 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC RECEIVES NASDAQ DELISTING NOTICE SUBJECT TO HEARING REQUEST
EX-99.1 to Form 6-K
Jan 30, 2025, 8:00 AM ET
(incorporated in the Cayman Islands with limited liability)
EX-99.1 to Form 6-K
Jan 30, 2025, 8:00 AM ET
Universe Pharmaceuticals INC (the “Company”)
EX-99.2 to Form 6-K
Dec 12, 2024, 4:31 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
EX-99.1 to Form 6-K
Nov 13, 2024, 8:02 AM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC ANNOUNCES SHARE CONSOLIDATION
EX-99.1 to Form 6-K
Nov 1, 2024, 4:00 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY
EX-99.1 to Form 6-K
Oct 10, 2024, 4:10 PM ET
LETTER OF YCM CPA INC. TO THE U.S. SECURITIES AND EXCHANGE COMMISSION DATED OCTOBER 10, 2024
EX-99.1 to Form 6-K
Sep 20, 2024, 4:15 PM ET
UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES
EX-99.1 to Form 6-K
Sep 20, 2024, 4:15 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Sep 20, 2024, 4:15 PM ET
PRESS RELEASE -- UNIVERSE PHARMACEUTICALS INC REPORTS FINANCIAL RESULTS FOR THE FIRST SIX MONTHS OF FISCAL YEAR 2024
EX-99.3 to Form 6-K
Sep 3, 2024, 4:10 PM ET
NOTICE AND PROXY STATEMENT OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED SEPTEMBER 3, 2024, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
Sep 3, 2024, 4:10 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Aug 31, 2023, 4:10 PM ET
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
EX-99.1 to Form 6-K
Aug 31, 2023, 4:10 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Aug 4, 2023, 8:30 AM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM MARKET VALUE OF PUBLICLY HELD SHARES
EX-99.1 to Form 6-K
Jul 27, 2023, 4:05 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC ANNOUNCES SHARE CONSOLIDATION
EX-99.1 to Form 6-K
May 24, 2023, 4:21 PM ET
NOTICE AND PROXY STATEMENT OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED MAY 24, 2023, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
May 24, 2023, 4:21 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Nov 14, 2022, 8:02 AM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
EX-99.1 to Form 6-K
Aug 29, 2022, 4:10 PM ET
NOTICE AND PROXY STATEMENT OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS, DATED AUGUST 29, 2022, TO BE MAILED TO THE SHAREHOLDERS OF THE COMPANY IN CONNECTION WITH THE 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.1 to Form 6-K
Aug 29, 2022, 4:10 PM ET
FORM OF PROXY CARD TO BE MAILED TO SHAREHOLDERS OF THE COMPANY FOR USE IN CONNECTION WITH THE 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY
EX-99.2 to Form 6-K
Aug 16, 2022, 4:15 PM ET
Condensed Consolidated Balance Sheets as of March 31, 2022 and September 30, 2021
EX-99.1 to Form 6-K
Aug 16, 2022, 4:15 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Aug 16, 2022, 4:15 PM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC REPORTS FISCAL YEAR 2021 FINANCIAL RESULTS
EX-99.3 to Form 6-K
Jul 19, 2022, 4:06 PM ET
UNIVERSE PHARMACEUTICALS INC RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY
EX-99.1 to Form 6-K
Jan 31, 2022, 8:05 AM ET
PRESS RELEASE - UNIVERSE PHARMACEUTICALS INC REPORTS FISCAL YEAR 2021 FINANCIAL RESULTS
EX-99.1 to Form 6-K
Dec 9, 2021, 4:20 PM ET
LETTER OF FRIEDMAN LLP TO THE U.S. SECURITIES AND EXCHANGE COMMISSION DATED DECEMBER 9, 2021
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Universe Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-600 reverse split on Apr 29, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is UPC.

Revenue growth-22.4% · median 7.3%

Gross margin35.3% · median 64.4%

Operating margin-16.3% · median 11.4%

Net margin-20.6% · median 20.0%

Company	Revenue	Growth
AZN	$29.01B	+16.2%
UPC	$17.86B	-22.4%
VTRS	$14.74B	+4.4%
TEVA	$14.10B	-15.2%
VRTX	$12.59B	+10.2%
AAPG	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: September 30
Employees: 225
Auditor: Enrome LLP
SEC CIK: 1809616

Advertisement
300 × 250